See safety info and boxed warning. The data were presented at the recent 2025 neuroscience. Austedo standard and xr tablets are currently indicated for adults for the treatment of chorea in huntington disease and tardive dyskinesia Austedo is the first vmat2 inhibitor approved by the us food and drug administration for adults with tardive dyskinesia 3 it is not currently approved for pediatric patients In a cohort of 27 participants, up to 77% reported enhancements in daily activities such as speech and eating after three months of treatment.
The routine use of benzodiazepines should be discouraged Because tardive dyskinesia most commonly develops after exposure to antipsychotics. The fda has approved austedo xr in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with huntington’s disease, according to the manufacturer Treating tardive dyskinesia the most common option for treating td is a vesicular monoamine transporter (vmat2) inhibitor See safety info including boxed warning.
OPEN
